Orion and Invenra announce discovery service and commercial license agreement to develop innovative bispecific antibody cancer therapeutics
ORION CORPORATION PRESS RELEASE 30 JANUARY 2025 at 16.00 EET Orion and Invenra announce discovery service and commercial ...
BioWorld7d
Orion and Invenra collaborate to develop bispecific antibody cancer therapeutics
Orion Corp. and Invenra Inc. have entered into a research collaboration to discover bispecific antibodies using Invenra’s B-Body platform.
Yahoo Finance7d
Orion and Invenra announce discovery service and commercial license agreement to develop innovative bispecific antibody cancer therapeutics
Orion Corporation (“Orion”) and Invenra Inc. (“Invenra”), an innovative biotechnology company with proprietary technologies for discovering novel therapeutics, today announced that they ...
Business Wire7d
Invenra and Orion Announce Discovery Service and Commercial License Agreement to Develop Innovative Bispecific Antibody Cancer Therapeutics
MADISON, Wis.--(BUSINESS WIRE)--Orion Corporation (“Orion”), a globally operating pharmaceutical company, and Invenra Inc., an innovative biotechnology company with proprietary technologies ...
Invenra and Orion Announce Discovery Service and Commercial License Agreement to Develop Innovative Bispecific Antibody Cancer Therapeutics
Orion Corporation ("Orion"), a globally operating pharmaceutical company, and Invenra Inc., an innovative biotechnology company with proprietary technologies for discovering novel therapeutics, today ...
Taiwan News7d
Orion and Invenra announce discovery service and commercial license agreement to develop innovative bispecific antibody cancer therapeutics
Orion Corporation (“Orion”) and Invenra Inc. (“Invenra”), an innovative biotechnology company with proprietary technologies for discovering novel therapeutics, today announced that they have entered ...